Press & Media

Nuletic in the media

Press kit, company facts, founder bio, and brand assets for journalists and media partners.

Company Overview

Nuleticis a physician-supervised biological optimization platform for men and women. Positioned as “The Digital Family Office for Biology,” Nuletic is designed to manage hormones, weight, cognition, and aging the way a family office manages wealth.

The platform will combine physician-supervised protocols (hormone therapy, GLP-1 weight management, peptide therapy) with AI-powered protocol optimization and continuous biomarker monitoring. Nuletic is designed to serve individuals, couples, and organizations.

Founded

2026

Headquarters

United States

Founder

Val Narodetsky

Stage

Pre-launch

Founder

Val Narodetsky, Founder & CEO

Val Narodetsky is a Ukrainian-born serial entrepreneur who arrived in the United States in 1998. As CEO of Odesa.co, he connects American tech companies with elite Eastern European engineering talent. Val has built multiple companies from zero to acquisition.

Nuletic was born from Val's personal experience with biological optimization. At 40, he worked with physicians to build a comprehensive protocol combining hormone therapy, peptides, and metabolic optimization. The transformation was profound, but the experience of accessing care was fragmented and frustrating. Nuletic is the platform he wished existed.

Val is available for interviews on: the grey-market peptide collapse, the future of physician-supervised optimization, GLP-1 medications and accessibility, the “Digital Family Office for Biology” concept, and building health tech companies.

Contact: press@nuletic.com

Story angles

Nuletic sits at the intersection of several trending stories. Journalists are welcome to use these angles and cite Nuletic's published research and guides.

The grey-market peptide collapse

64K people per month search for what happened to Peptide Sciences. The largest grey-market vendors have shut down following FDA enforcement. Millions of users need legitimate access.

Read the full guide →

GLP-1 medications: the accessibility crisis

Branded Wegovy costs $1,349/month. Compounded versions cost $150-300. The gap is driving a massive shift toward compounding pharmacies and telehealth.

Read the full guide →

RFK's peptide reclassification

The Feb 27, 2026 announcement that ~14 Category 2 peptides will return to legal compounding status. What it means for patients and providers.

Read the full guide →

Women's hormone health: the underserved majority

85% of women experience perimenopause symptoms. Most are told it's 'just stress.' The gap between what medicine offers and what women need.

Read the full guide →

The 'normal' problem in medicine

Reference ranges designed for population averages leave millions of patients symptomatic but 'normal.' The optimization movement is the response.

Read the full guide →

Corporate wellness beyond the gym membership

High-performance organizations are investing in biological optimization for their executives. Not yoga and fruit bowls. Hormones and biomarkers.

Read the full guide →

Brand assets

Download Nuletic brand assets for media use. Please use the logo as provided without modification.

By the numbers

90+

Evidence-based guides

24

Peptide encyclopedia entries

250+

Cited research references

8

Health pillars covered

3

Interactive health tools

50+

Glossary terms defined

Media inquiries

For press inquiries, interview requests, or media partnerships, contact us at:

press@nuletic.com

We typically respond within 24 hours.

Note: Nuletic is a pre-launch platform. Clinical services are not yet available. Content on nuletic.com is for informational purposes only and does not constitute medical advice.

Join Waitlist